These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19398903)

  • 1. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.
    Luo Y; Hradil VP; Frost DJ; Rosenberg SH; Gordon GB; Morgan SJ; Gagne GD; Cox BF; Tahir SK; Fox GB
    Anticancer Drugs; 2009 Jul; 20(6):483-92. PubMed ID: 19398903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
    Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-selective antivascular effects of the novel anti-mitotic compound A-318315: An in vivo rat regional haemodynamic study.
    Segreti JA; Brooks KA; Marsh KC; Bauch JL; Lan Y; Thomas Lin C; Rosenberg SH; Sham HL; Reinhart GA; Cox BF; Polakowski JS
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):636-40. PubMed ID: 20132238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
    Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
    Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
    Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
    Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
    Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
    J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
    Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity.
    Deng ZT; Feng T; Wang P; Qi X; Chen XH; Li YX; Song CL; Geng MY; Li J
    Biochem Pharmacol; 2011 Dec; 82(12):1832-42. PubMed ID: 21920350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
    Durrant D; Corwin F; Simoni D; Zhao M; Rudek MA; Salloum FN; Kukreja RC; Fatouros PP; Lee RM
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):191-200. PubMed ID: 18365199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
    Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
    Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.